We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
- Authors
Batist, G; Ramakrishnan, G; Rao, C S; Chandrasekharan, A; Gutheil, J; Guthrie, T; Shah, P; Khojasteh, A; Nair, M K; Hoelzer, K; Tkaczuk, K; Park, Y C; Lee, L W
- Abstract
To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 5, p1444
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.5.1444